Comparison of Levofloxacin versus Moxifloxacin for Multidrug-Resistant Tuberculosis

Authors
Won-Jung KohSeung Heon LeeYoung Ae KangChang-Hoon LeeJae Chol ChoiJae Ho LeeSeung Hun JangKwang Ha YooKi Hwan JungKi Uk KimSang Bong ChoiYon Ju RyuKyung Chan KimSoojung UmYong Soo KwonYee Hyung KimWon-Il ChoiKyeongman JeonYong Il HwangSe Joong KimYoung Seok LeeEun Young HeoJuhee LeeYeo WoonKiTae Sun ShimJae-Joon Yim
Department
Dept. of Internal Medicine (내과학)
Issue Date
2013
Citation
American Journal of Respiratory and Critical Care Medicine, Vol.188(7) : 858-64, 2013
ISSN
1073-449X
Abstract
Rationale: Levofloxacin (LFX) and moxifloxacin (MXF) are the two most frequently recommended fluoroquinolones for treatment of patients with multidrug-resistant tuberculosis (MDR-TB). However, studies comparing the effectiveness of LFX and MXF among patients with MDR-TB are lacking. Objectives: To compare the effectiveness of LFX and MXF in terms of culture conversion after 3 months of treatment for MDR-TB. Methods: In this prospective multicenter randomized open label trial, we randomly assigned 182 patients with MDR-TB (sensitive to LFX and MXF) to receive either LFX (750 mg/day; 90 patients) or MXF (400 mg/day; 92 patients) with a background drug regimen. The primary outcome was the proportion of patients who achieved sputum culture conversion at 3 months of treatment. Secondary outcomes were time to culture conversion and time to smear conversion, with data censored at 3 months, and the proportions of adverse drug reactions. Measurements and Main Results: At 3 months of treatment, 68 (88.3%) of the 77 patients in the LFX group and 67 (90.5%) of the 74 in the MXF group showed conversion to negative sputum cultures (odds ratio for LFX compared with MXF, 0.78; 95% confidence interval, 0.27–2.20). Adverse drug reactions were reported in six patients (7.7%) in the LFX group and four (5.2%) in the MXF group (P = 0.75). Conclusions: The choice of LFX or MXF for treatment of patients with MDR-TB may not affect sputum culture conversion at 3 months of treatment. Clinical trial registered with www.clinicaltrials.gov (NCT 01055145). KEYWORDS: multidrug-resistant tuberculosis, fluoroquinolone, moxifloxacin, levofloxacin Read More: http://www.atsjournals.org/doi/abs/10.1164/rccm.201303-0604OC#.VoxntU8axZQ
URI
http://kumel.medlib.dsmc.or.kr/handle/2015.oak/34947
Appears in Collections:
1. Journal Papers (연구논문) > 1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
Keimyung Author(s)
최원일
Full Text
https://www.atsjournals.org/doi/abs/10.1164/rccm.201303-0604OC?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed
File in this Item
 사서에게 요청하기
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE